Nyxoah Sa (BE:NYXH) has released an update.
Nyxoah SA, a medical tech firm specializing in Obstructive Sleep Apnea treatments, has reported positive Q1 2024 results, including the successful achievement of primary endpoints in the DREAM U.S. pivotal study, setting the stage for FDA approval by end of 2024. The company also announced a solid financial position with a total cash of €44.3 million, alongside the appointment of Dr. Maurits S. Boon as Chief Medical Officer, and strategic partnerships to improve patient access.
For further insights into BE:NYXH stock, check out TipRanks’ Stock Analysis page.